Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est

Loading news article.

Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est | WAPE

Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est

Article summary

Related companies

Comments —